Article
Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies.
Molecular medicine (Cambridge, Mass.) - 29 Nov 2025
Nesnadna Romana, Petrackova Anna, Minarik Jiri, Latal Vojtech, Manakova Jirina, Papajik Tomas, Kriegova Eva
Abstract excerpt
Multiple myeloma (MM) with high-risk (HR) genetic abnormalities has poor prognosis, despite the use of novel therapeutic agents. However, the individual contribution of specific HR genetic abnormalities or their co-occurrence to poor outcomes, especially in the era of novel agents, remains unclear. This study evaluated the impact of multi-hit TP53 (del(17p) and TP53 mutation or ≥ 2 TP53 mutations) compared with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.